Surgery Branch
Head, Tumor Immunology Section
Branch Chief

National Cancer Institute
9000 Rockville Pike
Building 10, Room 3-3940
Bethesda, MD 20892

Phone: 301-496-4164
Fax: 301-402-1738
SAR@nih.gov

Dr. Rosenberg is chief of surgery at the National Cancer Institute (NCI) in Bethesda, Md., and a professor of surgery at the Uniformed Services University of the Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C.

Dr. Rosenberg received his B.A. and M.D. degrees from The Johns Hopkins University in Baltimore, Md., and his Ph.D. in biophysics from Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Mass., Dr. Rosenberg became chief of surgery at NCI, a position he has held to the present time.

Dr. Rosenberg's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with melanoma or other cancers. Click on the trial(s) below for additional details, including a summary of eligibility criteria, study outline, and information on how to contact the study team directly.

Phase I/II Study of B-Cell Malignancies Using T Cells Expressing an Anti-DC19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T-Cell Transfer NCI-09-C-0082

Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines NCI-09-C-0051

Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes NCI-09-C-0047

Transfer of Autologous T Cells Transduced With the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma NCI-08-C-0162

Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization NCI-08-C-0056

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization NCI-08-C-0055

Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma NCI-07-C-0210

Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma NCI-07-C-0176

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes NCI-07-C-0175

Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100: 154:162 TCR Gene Engineered Lymphocytes NCI-07-C-0174

A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma NCI-07-C-0114

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma NCI-06-C-0069